Raloxifene, an oestrogen-receptor-beta-targeted therapy, inhibits androgen-independent prostate cancer growth: results from preclinical studies and a pilot phase II clinical trial

BJU International
Ronald L ShazerDavid B Agus

Abstract

To determine, in preclinical in vivo animal and in clinical studies, whether raloxifene (a selective oestrogen-receptor (ER) modulator that targets ER-beta and induces apoptosis in vitro in androgen-independent prostate cancer, AIPC cells) affects prostate cell differentiation, proliferation and carcinogenesis, and in the pilot phase II clinical trial, the response rate and duration of patients with AIPC treated with a daily oral dose of raloxifene. Tumour proliferation rate in response to raloxifene treatment, and molecular markers of cell cycle and apoptosis, were evaluated in established ER-beta-positive androgen-dependent (AD) CWR22 and AI CWRSA9 human xenograft prostate cancer models. Twenty-one patients with AIPC and evidence of disease progression were enrolled into the clinical trial and given daily oral raloxifene. There was significant growth inhibition by raloxifene in the ADPC and AIPC xenograft models (CWR22 68%, P < 0.010; CWRSA9 64%, P < 0.001), with no tumour regression. There was evidence of G1 arrest by increased p27kip1 expression in the raloxifene-treated group. Eighteen patients comprised the efficacy analysis, as three withdrew before the first evaluation. At the first evaluation, five men had stable disea...Continue Reading

References

Nov 5, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G J BubleyG Wilding
Jul 5, 2001·The American Journal of Pathology·S Signoretti, M Loda
Aug 30, 2002·The Aging Male : the Official Journal of the International Society for the Study of the Aging Male·A VermeulenI van Pottelberg
Feb 14, 2003·The New England Journal of Medicine·B Lawrence Riggs, Lynn C Hartmann
Apr 15, 2004·European Journal of Endocrinology·Erik J J DuschekCoen Netelenbos

❮ Previous
Next ❯

Citations

May 13, 2010·BMC Medical Genomics·Chirag J Patel, Atul J Butte
Jan 1, 2007·Indian Journal of Urology : IJU : Journal of the Urological Society of India·Vivek Vijjan, Deepak Dubey
Nov 5, 2013·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Margherita PiccolellaAngelo Poletti
Apr 2, 2014·BioMed Research International·Sebastien TaurinKhaled Greish
Apr 1, 2009·Cellular and Molecular Life Sciences : CMLS·Stephan EllmannPamela L Strissel
Sep 17, 2015·Journal of Drug Targeting·Tara PritchardSebastien Taurin
Sep 6, 2011·Endocrinology and Metabolism Clinics of North America·Shuk-Mei HoYuet-Kin Leung
Jul 12, 2008·The Prostate·Manpreet K ChadhaDonald L Trump
Jan 31, 2007·Annals of the New York Academy of Sciences·Shuk-Mei HoIrving Chung
Oct 31, 2009·Journal of Cellular and Molecular Medicine·Lluis-A Lopez-Barcons
Oct 11, 2007·Differentiation; Research in Biological Diversity·William A RickeGerald R Cunha
Mar 29, 2019·The Journal of Pharmacy and Pharmacology·Giovanna Cassone SalataWellerson Rodrigo Scarano
Aug 23, 2018·Prostate Cancer and Prostatic Diseases·Ryan W DobbsMichael R Abern
Feb 12, 2020·International Journal of Molecular Sciences·Paola OstanoGiovanna Chiorino
Oct 28, 2015·Oncotarget·Erika Di ZazzoAntimo Migliaccio
Nov 30, 2010·Expert Review of Anticancer Therapy·Fred Saad, Marc Colombel
Feb 7, 2018·Frontiers in Oncology·Erika Di ZazzoGabriella Castoria

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis